Affiliation:
1. Laboratoires Réunis Kutter-Lieners-Hastert, Junglinster, Luxembourg
2. Institut für Medizinische Virologie, Universitätskliniken Frankfurt, Frankfurt, Germany
Abstract
ABSTRACT
Combined antigen and antibody screening (fourth-generation) assays reduce the diagnostic window period between the time of human immunodeficiency virus (HIV) infection and laboratory diagnosis by 4 days, on average, in comparison to antibody-only (third generation) enzyme immunoassays (EIAs). The aim of the present study was to assess whether the new VIDAS HIV DUO Ultra (Biomérieux, Marcy-l'Etoile, France) showed an improved sensitivity and specificity in comparison to licensed fourth-generation assays. A total of 16 seroconversion panels, 15 cell culture supernatants infected with different HIV type 1 (HIV-1) subtypes, and 257 potentially cross-reactive serum samples were tested with VIDAS DUO HIV Ultra, Genscreen Plus HIV Ag-Ab, Enzygnost HIV Integral, Enzymun-Test HIV Combi, Genscreen HIV 1/2, version 2 (third-generation EIA), and Genetic Systems HIV-1 Ag EIA (p24 antigen assay). VIDAS HIV DUO Ultra showed a comparable sensitivity to the single p24 antigen assay in seroconversion panels and a dilution series of virus lysates. The diagnostic window was reduced with VIDAS HIV DUO Ultra by 3.82 days, on average, in comparison with the fourth-generation assay with the lowest sensitivity of the antigen detection module. HIV-1 infection was detected 5.88 days earlier than with third-generation EIA. The mean time delay between reverse transcription-PCR and VIDAS HIV DUO Ultra was only 2.31 days. The specificity of fourth-generation assays after retesting ranged between 98.1 and 100%. In conclusion, VIDAS HIV DUO Ultra can replace single-antigen screening for laboratory diagnosis and screening of HIV infection in blood donors. There was no evidence for a second diagnostic window due to impaired sensitivity of the antibody detection module of all the fourth-generation EIAs evaluated in the present study. The specificity after initial and/or repeated testing of VIDAS HIV DUO Ultra was equivalent to that of a third-generation assay.
Publisher
American Society for Microbiology
Reference27 articles.
1. Alter, H. J., J. S. Epstein, S. G. Swenson, M. J. Van Raden, J. W. Ward, R. A. Kaslow, J. E. Menitove, H. G. Klein, S. G. Sandler, M. H. Sayers, I. K. Hewlett, A. I. Chernoff, et al. 1990. Prevalence of human immunodeficiency virus type 1 p24 antigen in U. S. blood donors—an assessment of the efficacy of testing in donor screening. N. Engl. J. Med.323:1312-1317.
2. Aubuchon, J. P., J. D. Birkmeyer, and M. P. Busch. 1997. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion45:45-51.
3. Performance of the Amplicor human immunodeficiency virus type 1 PCR and analysis of specimens with false-negative results
4. Brust, S., H. Duttmann, J. Feldner, L. Gürtler, R. Thorstensson, and F. Simon. 2000. Shortening of the diagnostic window with the new combined HIV p24 antigen and anti-HIV-1/2/O screening test. J. Virol. Methods90:153-165.
5. Nicht-parametrierbare Methoden 1978
Cited by
51 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献